Public Funding for Oxsonics Limited

The TSB Biomedical Catalyst Fund will be instrumental in enabling OxSonics Limited to develop a prototype of its first product, “SonoTran”, a low-cost therapeutic ultrasound device and associated consumables for the non-invasive targeted and enhanced delivery of cancer drugs to solid tumours. SonoTran has the capability to overcome the greatest challenge facing solid tumour drug delivery: poor penetration of even the smartest drugs deep into solid tumours. A key feature of OxSonics core technology is the ability to map and intra-operatively monitor treatment in real-time and in 3D – a feature that has the potential to transform healthcare practice. The platform technology can also be applied to a range of surgical applications including the repair of intervertebral discs for the treatment of chronic low back pain. TSB funding will initially enable the creation of 4 new UK jobs, rising to 24 new UK jobs by 2019.